|
|
|
|
LEADER |
02539nam a2200421Ia 4500 |
001 |
10-1093-femsle-fnac020 |
008 |
220425s2022 CNT 000 0 und d |
020 |
|
|
|a 03781097 (ISSN)
|
245 |
1 |
0 |
|a Bacteriophage Sf6 host range mutant that infects Shigella flexneri serotype 2a2strains
|
260 |
|
0 |
|b Oxford University Press
|c 2022
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1093/femsle/fnac020
|
520 |
3 |
|
|a Shigella flexneri serotype 2a2 (II:9;10) is the most prevalent strain in causing bacillary dysentery in developing countries. Chemical modifications such as glucosylation, O-acetylation, and phosphoethanolamine modifications of lipopolysaccharide (LPS) O antigen (Oag) contribute to the emergence of various serotypes. Sf6 is a Shigella-specific bacteriophage that infects only a limited range of S. flexneri serotypes [X, Y]. LPS Oag is the primary receptor for bacteriophage Sf6 where it uses its tailspike protein (TSP) in binding and hydrolysing LPS Oags. Sf6TSP has recently been shown to be capable of hydrolysing the LPS Oag of Type II strains, albeit modestly. Phage therapy has regained attention in recent years as an alternative therapeutic approach. Therefore, this study aimed to expand the host range of Sf6 to the prevalent S. flexneri serotype 2a2 strain. We discovered a new lytic Sf6 host range mutant that is capable of infecting S. flexneri serotype 2a2 and identified residues in Sf6TSP that may potentially be involved in binding and hydrolysing serotype 2a2 LPS Oag. This work increased the limited Shigella-specific bacteriophage collection and may be useful in the future for phage therapy and/or biocontrolling of S. flexneri in contaminated food and water. © 2022 The Author(s). Published by Oxford University Press on behalf of FEMS.
|
650 |
0 |
4 |
|a bacteriophage
|
650 |
0 |
4 |
|a bacteriophage
|
650 |
0 |
4 |
|a Bacteriophages
|
650 |
0 |
4 |
|a chemistry
|
650 |
0 |
4 |
|a Dysentery, Bacillary
|
650 |
0 |
4 |
|a genetics
|
650 |
0 |
4 |
|a host range
|
650 |
0 |
4 |
|a host range mutant
|
650 |
0 |
4 |
|a Host Specificity
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a Humans
|
650 |
0 |
4 |
|a O antigen
|
650 |
0 |
4 |
|a O Antigens
|
650 |
0 |
4 |
|a Serogroup
|
650 |
0 |
4 |
|a serotype
|
650 |
0 |
4 |
|a serotype 2a
|
650 |
0 |
4 |
|a Sf6
|
650 |
0 |
4 |
|a Shigella flexneri
|
650 |
0 |
4 |
|a Shigella flexneri
|
650 |
0 |
4 |
|a Shigella flexneri
|
650 |
0 |
4 |
|a shigellosis
|
650 |
0 |
4 |
|a tailspike protein
|
700 |
1 |
|
|a Morona, R.
|e author
|
700 |
1 |
|
|a Teh, M.Y.
|e author
|
700 |
1 |
|
|a Tran, E.N.H.
|e author
|
773 |
|
|
|t FEMS Microbiology Letters
|